3p22.1 and 10q22.3 Deletions Detected by Fluorescence In Situ Hybridization (FISH): A Potential New Tool for Early Detection of Non-small Cell Lung Cancer.

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

The evolution of treatment outcomes for resected stage IIIA non–small cell lung cancer over 16 years at a single institution Linda W. Martin, MD, Arlene.

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: Significance of microscopically positive circumferential radial margins

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients Lecia V. Sequist, MD, MPH, Sunitha Nagrath, PhD, Mehmet.

Puja Gaur, MD, Wayne L. Hofstetter, MD, B

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Application of the revised lung cancer staging system (IASLC Staging Project) to a cancer center population Edmund S. Kassis, MD, Ara A. Vaporciyan,

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy Apar Pataer, MD, PhD, Neda Kalhor,

Non-Small Cell Lung Cancer Resection in Lymphoma Patients

Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group Shadia Jalal,

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

David C. Rice, MB, BCh, Matthew A

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Anthony J. Ascioti, MD, Wayne L. Hofstetter, MD, Michael J

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Dhakshina Moorthy Ganeshan, MD, Arlene M

EGFR Dinucleotide Repeat Polymorphism as a Prognostic Indicator in Non-small Cell Lung Cancer Sarita Dubey, MD, Patricia Stephenson, ScD, Donna E. Levy,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Treatment trends in early-stage lung cancer in the United States, 2004 to 2013: A time- trend analysis of the National Cancer Data Base Kathryn E. Engelhardt,

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

“The Best-Laid Plans … Often go Awry …”

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Clinical Significance of Epidermal Growth Factor Receptors in Non-small Cell Lung Cancer and a Prognostic Role for HER2 Gene Copy Number in Female Patients

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Erratum Journal of Thoracic Oncology

Journal of Thoracic Oncology

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang,

Toni-Maree Rogers, BMLS, Prudence A

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

David C. Rice, MB, BCh, Jeremy J. Erasmus, MD, Craig W

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD,

Predictors of Recurrent Pulmonary Metastases and Survival After Pulmonary Metastasectomy for Colorectal Cancer Shanda H. Blackmon, MD, MPH, Elizabeth.

Mara B. Antonoff, MD, Wayne L. Hofstetter, MD, Arlene M

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

A Review of First-Line Treatment for Small-cell Lung Cancer

Improved Long-Term Outcome With Chemoradiotherapy Strategies in Esophageal Cancer Stephen G. Swisher, MD, Wayne Hofstetter, MD, Ritsuko Komaki, MD, Arlene.

Jenifer L. Marks, MD, Wayne Hofstetter, MD, Arlene M

The risk of second primary tumors after resection of stage I nonsmall cell lung cancer David Rice, MB, BCh, Hyung-Woo Kim, MS, Anita Sabichi, MD, Scott.

Presentation transcript:

3p22.1 and 10q22.3 Deletions Detected by Fluorescence In Situ Hybridization (FISH): A Potential New Tool for Early Detection of Non-small Cell Lung Cancer (NSCLC) Sai Yendamuri, MB, BS, Ara A. Vaporciyan, MD, Tanweer Zaidi, MD, Lei Feng, MS, Ricardo Fernandez, BS, Nebiyou B. Bekele, PhD, Wayne L. Hofstetter, MD, Feng Jiang, MD, PhD, Reza J. Mehran, MD, David C. Rice, MD, Margaret R. Spitz, MD, MPH, Stephen G. Swisher, MD, Garrett L. Walsh, MD, Jack A. Roth, MD, Ruth L. Katz, MD Journal of Thoracic Oncology Volume 3, Issue 9, Pages 979-984 (September 2008) DOI: 10.1097/JTO.0b013e3181834f3a Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Schematic showing the areas of biopsy. NBB, brush biopsy of the mainstem bronchus on the side opposite the tumor; TBB, brush biopsy of the mainstem bronchus on the side of the tumor; TAB, touch prep of the bronchus adjacent to the tumor; NTP, touch prep of normal lung parenchyma; TTP, touch prep of the tumor. Journal of Thoracic Oncology 2008 3, 979-984DOI: (10.1097/JTO.0b013e3181834f3a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Sample slides of the FISH analysis. Orange signals are centromeric signals. Green signals indicate 3p22.1 and 10q22.3 probes. The cells with fewer green signals than orange signals show cells that have deletions at either the 3p22.1 (A) and 10q22.3 (B) loci. Journal of Thoracic Oncology 2008 3, 979-984DOI: (10.1097/JTO.0b013e3181834f3a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 The deletion rate at 3p22.1 and 10q22.3 increases systematically as one progresses from tissue away from the tumor towards the tumor itself. The deletion rate is significantly greater in brush biopsies from mainstem bronchi on the tumor side (TBB) compared with the normal side (NBB) (p < 0.05). Similarly, the deletion rate at the tumor itself (TTP) is significantly greater than TBB itself (p < 0.05). Journal of Thoracic Oncology 2008 3, 979-984DOI: (10.1097/JTO.0b013e3181834f3a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 A, 3p22.1 deletions at TBB correlate with 3p22.1 deletions at TTP. Spearman coeff = 0.61, p < 0.00001. B, 10q22.3 deletions at TAB correlate with 10q22.3 deletions at TTP. Spearman coeff = 0.64, p < 0.00001. Journal of Thoracic Oncology 2008 3, 979-984DOI: (10.1097/JTO.0b013e3181834f3a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Survival curves for patients separated by median deletion rate at the 10 q locus at (A) TTP (p = 0.176) (B) TBB (p = 0.153). Journal of Thoracic Oncology 2008 3, 979-984DOI: (10.1097/JTO.0b013e3181834f3a) Copyright © 2008 International Association for the Study of Lung Cancer Terms and Conditions